Breaking News, Collaborations & Alliances

WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs

Will combine WuXi XDC's ADC technology platform with Earendil Labs' AI-driven antibody discovery and development capabilities to address significant unmet medical needs.

Author Image

By: Charlie Sternberg

Associate Editor

Jimmy Li, PhD, CEO of WuXi XDC (left); Jian Peng, PhD, CEO of Earendil Labs (right).

WuXi XDC Cayman Inc., a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, has entered a strategic collaboration with Earendil Labs on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters